Latest news
{{'2025-09-15T12:00:52Z' | dateFormatFilter}}
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
{{'2025-09-10T05:00:45Z' | dateFormatFilter}}
Novo Nordisk to streamline operations and reinvest for growth
{{'2025-09-05T06:01:42Z' | dateFormatFilter}}
Novo Nordisk to present new semaglutide data on ‘food noise’, body composition and cardiovascular benefits, as well as pipeline data at the EASD diabetes congress
Investors
Share price
{{priceData.date}} {{priceData.time}}
{{priceData.currentPrice}}
{{priceData.currency}}
Go to stock watch
{{priceData.change}} {{priceData.currency}}
